Skip to main content
. Author manuscript; available in PMC: 2010 May 29.
Published in final edited form as: J Immunol. 2008 Oct 15;181(8):5189–5193. doi: 10.4049/jimmunol.181.8.5189

Figure 2. 9-cisRA inhibition of NFκB activation.

Figure 2

(a) 9-cisRA-mediated, dose-dependent inhibition of a luciferase reporter containing the human TSLP promoter. (b) 9-cisRA inhibition of a luciferase reporter containing human TSLP promoter with putative RARE site deleted. (c) Dose-dependent inhibition by 9-cisRA of a luciferase reporter containing multiple NFκB binding sites. For each set of experiments, 16HBEo¯ cells were transiently transfected with the indicated luciferase constructs, and 19 hr after transfection cells were incubated for 5 h in 1 ng/ml IL-1β in the absence or presence of 9-cisRA, at the indicated concentration. At that time cells were harvested and lysates prepared for determination of luciferase activity. Luciferase activity in the whole cell lysate was normalized to β-galactosidase activity. Data are the mean ± SD of triplicate data points from a representative experiment.